

*(Use as many sheets as necessary)*

Application Number	10/551,466
§ 371(c) Date:	August 7, 2006
First Named Inventor	Ji Hoon JEONG
Art Unit	1635
Examiner Name	Pitrak, Jennifer K.
Attorney Docket Number	2229.0020000/JUK/SMW/X-S

Sheet	1	of	1
-------	---	----	---

[illegible]

Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	FP2	WO 2004/009769 A2	01-29-2004	Tolentino <i>et al.</i>		
	FP3	WO 2004/076630 A2	09-10-2004	Monahan <i>et al.</i>		
	FP4	WO 2004/087931 A1	10-14-2004	Jeong <i>et al.</i>		
	FP5	EP 1 801 210 A1	06-27-2007	Nagasaki <i>et al.</i>		

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under MPEP Standard 609. If possible, Applicant is to make a check in multiple English language Translation is attached.

Substitute for form 1449/PTO  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/551,466	
			§ 371(c) Date:	August 7, 2006	
			First Named Inventor	Ji Hoon JEONG	
			Art Unit	1635	
			Examiner Name	Pitrak, Jennifer K.	
Sheet	1	of	2	Attorney Docket Number	2229.0020000/JUK/SMW/X-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL4	BONORA, "Polymer-conjugated Bioactive Oligonucleotides," <i>Journal of Bioactive and Compatible Polymers</i> 17:375-389 (September 2002) Sage Publications	
	NPL5	HEALY <i>et al.</i> , "Pharmacokinetics and Biodistribution of Novel Aptamer Compositions," <i>Pharmaceutical Research</i> 21:2234-2246 (2004) Springer Science+Business Media, Inc.	
	NPL6	JEONG <i>et al.</i> , "Novel Intracellular Delivery System of Antisense Oligonucleotide by Self-Assembled Hybrid Micelles Composed of DNA/PEG Conjugate and Cationic Fusogenic Peptide," <i>Bioconjugate Chem.</i> 14:473-479 (March 2003) American Chemical Society	
	NPL7	JEONG <i>et al.</i> , "A New Antisense Oligonucleotide Delivery System Based on Self-Assembled ODN-PEG Hybrid Conjugate Micelles," <i>Journal of Controlled Release</i> 93:183-191 (December 2003) Elsevier B.V.	
	NPL8	JONES <i>et al.</i> , "Conjugates of Double-Stranded Oligonucleotides with Poly(ethylene glycol) and Keyhole Limpet Hemocyanin: A Model for Treating Systemic Lupus Erythematosus," <i>Bioconjugate Chem.</i> 5:390-399 (1994) American Chemical Society	
	NPL9	KAWAGUCHI <i>et al.</i> , "Stability, Specific Binding Activity, and Plasma Concentration in Mice of an Oligodeoxynucleotide Modified at 5'-Terminal with Poly(ethylene glycol)," <i>Biol. Pharm. Bull.</i> 18:474-476 (1995) Pharmaceutical Society of Japan	
	NPL10	KIM <i>et al.</i> , "Target-Specific Gene Silencing by siRNA Plasmid DNA Complexed with Folate-Modified Poly(ethylenimine)," <i>Journal of Controlled Release</i> 104:223-232 (2005) Elsevier B.V.	
	NPL11	KIM <i>et al.</i> , "PEG conjugated VEGF siRNA for anti-angiogenic gene therapy," <i>Journal of Controlled Release</i> 116:123-129 (2006) Elsevier B.V.	
	NPL12	LEE <i>et al.</i> , "Intracellular siRNA Delivery System Using Polyelectrolyte Complex Micelles Prepared from VEGF siRNA-PEG Conjugate and Cationic Fusogenic Peptide," <i>Biochemical and Biophysical Research Communications</i> 357:511-516 (2007) Elsevier Inc.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BW/**  
 If you need assistance in completing the form, call 1-800-PTO-9496 (1-800-786-9496) and select option 2.

Substitute for form 1449/PTO  <b>FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/551,466
				§ 371(c) Date:	August 7, 2006
				First Named Inventor	Ji Hoon JEONG
				Art Unit	1635
				Examiner Name	Pitrak, Jennifer K.
Sheet	2	of	2	Attorney Docket Number	2229.0020000/JUK/SMW/X-S

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL13	OISHI <i>et al.</i> , "Smart Polyion Complex Micelles for Targeted Intracellular Delivery of PEGylated Antisense Oligonucleotides Containing Acid-Labile Linkages," <i>ChemBioChem</i> 6:718-725 (2005) Wiley-VCH Verlag GmbH & Co. Weinheim	
	NPL14	OISHI <i>et al.</i> , "Lactosylated Poly(ethylene glycol)-siRNA Conjugate through Acid-Labile $\beta$ -Thiopropionate Linkage to Construct pH-Sensitive Polyion Complex Micelles Achieving Enhanced Gene Silencing in Hepatoma Cells," <i>J. Am. Chem. Soc.</i> 127:1624-1625 (2005) American Chemical Society	

1302425.1

Examiner Signature	/Brian Whiteman/	Date Considered	05/09/2011
-----------------------	------------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BW/**  
*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*